<?xml version="1.0" encoding="UTF-8"?><rss version="2.0"><channel><title><![CDATA[Neos Therapeutics, Inc. 보도자료 - 뉴스와이어]]></title><link>https://www.newswire.co.kr/?md=A10&amp;act=article&amp;no=22365></link><description><![CDATA[Neos Therapeutics, Inc. 보도자료 - 뉴스와이어 RSS 서비스]]></description><lastBuildDate>Sat, 16 May 2026 19:33:15 +0900</lastBuildDate><copyright>Copyright (c) 2004~2026 Korea Newswire All rights reserved</copyright><language>ko-KR</language><item><title><![CDATA[Neos Therapeutics Announces Issuance of New Patent Covering Composition of Matter for Company’s Novel ADHD Products]]></title><link>https://www.newswire.co.kr/newsRead.php?no=750330</link><description><![CDATA[DALLAS & FORT WORTH, Texas--(Business Wire/Korea Newswire)--Neos Therapeutics, Inc. (“Neos” or “the Company”), a highly differentiated oral drug delivery company with a portfolio of proprietary technologies and a late-stage pipeline of innovative controlled release (CR) products for ADHD, announced today that it has been granted a patent covering its novel amphetamine ADHD products.  Neos has developed a...]]></description><pubDate>Thu, 15 May 2014 20:05:00 +0900</pubDate></item><item><title><![CDATA[네오스 테라퓨틱스, ADHD 신약 물질 구성에 관한 신규 특허 등록 발표]]></title><link>https://www.newswire.co.kr/newsRead.php?no=750331</link><description><![CDATA[댈라스 및 포트워스, 텍사스--(Business Wire/뉴스와이어)--네오스 테라퓨틱스(Neos Therapeutics, Inc., 이하 네오스)는 암페타민 성분의 주의력결핍 과잉행동장애(ADHD) 신약에 대한 특허를 획득했다고 오늘 발표했다. 네오스는 고도로 차별화된 경구용 약물 전달 기술 전문 제약회사로 특허 기술 포트폴리오와 임상 후기 단계의 혁신적인 서방형(CR) 약품 파이프라인(후보물질)을 보유하고 있다.  네오스는 복효형(XR) 암페타민 구...]]></description><pubDate>Thu, 15 May 2014 20:05:00 +0900</pubDate></item></channel></rss>